CJC-1295 without DAC (Drug Affinity Complex) is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It’s a modified version of the first 29 amino acids of natural GHRH, designed for enhanced stability and a longer half-life compared to unmodified GHRH. Unlike CJC-1295 with DAC (which has a half-life of ~6-8 days due to albumin binding), the “No DAC” version has a shorter half-life of about 30 minutes to 2 hours, making it suitable for more frequent dosing to mimic natural GH pulses.

Key Chemical Details:

• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 (with specific modifications like norleucine substitution).
• Molecular Formula: C152H252N44O42.
• Molecular Weight: ~3,369 Da.
• Developed by ConjuChem Biotechnologies in the early 2000s for research into GH deficiency and anti-aging.

Primary Uses and Mechanism

CJC-1295 No DAC acts as a GHRH agonist, binding to pituitary GHRH receptors to stimulate pulsatile release of endogenous growth hormone (GH) and subsequently insulin-like growth factor 1 (IGF-1). This leads to:

• Increased lean muscle mass and fat loss.
• Improved recovery, sleep quality, and collagen synthesis.
• Potential benefits for anti-aging, injury repair, and metabolic health.

It’s commonly used in research settings or by biohackers/bodybuilders, often stacked with a growth hormone-releasing peptide (GHRP) like Ipamorelin or GHRP-6 for synergistic GH pulses. Evidence comes from preclinical studies (e.g., Teichman et al., 2006, showing 2-10x GH increase) and anecdotal reports, though human clinical trials are limited post-patent issues.

Dosage and Administration (Research Contexts)

• Typical Research Dose: 100-200 mcg per subcutaneous injection, 1-3 times daily (e.g., post-workout, bedtime).
• Stack Example: 100 mcg CJC-1295 No DAC + 100 mcg Ipamorelin, 2-3x/day.
• Reconstituted with bacteriostatic water; store lyophilized at -20°C, reconstituted at 2-8°C.
• Cycle: 8-12 weeks on, 4 weeks off to avoid pituitary desensitization.

Evidence: A 2005 study (Albazali et al.) in healthy males showed 100 mcg IV dose increased GH by 5-10x for 1-2 hours, with IGF-1 elevation over 24 hours. No large RCTs for performance enhancement.

Side Effects and Risks

Common (mild, transient):

• Flushing, warmth, or head rush (5-15 min post-injection).
• Water retention, numbness in extremities.

Rare/Serious:

• Potential insulin resistance with chronic high doses.
• GH-related risks: carpal tunnel, joint pain, increased cancer risk if predisposed (theoretical, based on GH/IGF-1 axis).
• Not FDA-approved for human use; sourced as “research chemical” (purity varies; third-party testing advised).

Legality and Availability

• Status: Research peptide only (not for human consumption in most countries). Banned by WADA for athletes (Class S2.2). Legal to purchase for lab research in the US/EU from vendors like Peptide Sciences or Limitless Life Nootropics.
• Purity Concerns: HPLC-tested products should be >98%; avoid unverified sources to prevent contaminants like heavy metals.

For deeper dives, check PubMed (search “CJC-1295 pharmacokinetics”) or research papers like “Prolonged Stimulation of Growth Hormone by CJC-1295” (J Clin Endocrinol Metab, 2006). Always consult a physician for personal use—I’m not medical advice.